Portal de Periódicos da CAPES

Genetically engineered superantigens as tolerable antitumor agents

1997; National Academy of Sciences; Volume: 94; Issue: 6 Linguagem: Inglês

10.1073/pnas.94.6.2489

1091-6490

Johan Hansson, Lennart Ohlsson, Robert Persson, Gunnar Andersson, Nils‐Gunnar Ilbäck, Mark J. Litton, Terje Kalland, Mikael Dohlsten,

RNA Interference and Gene Delivery

Superantigens (SAg) are a family of bacterial and viral proteins with strong immunostimulatory properties. SAg bound to major histocompatibility complex (MHC) class II molecules activate a high frequency of T cells and represent the most potent known activators of T cells to date. To explore the use of SAg for T cell-based tumor therapy we have created a tumor-reactive SAg by engineering a fusion protein composed of a tumor-reactive mAb (C215Fab) and the bacterial SAg staphylococcal enterotoxin A (SEA). A point mutation D227A was introduced at the major MHC class II binding site in SEA to reduce systemic toxicity. Treatment of tumor bearing mice with the Fab–SEA D227A fusion protein resulted in profound antitumor effects with a markedly reduced toxicity as compared with the wild-type Fab–SEA fusion protein. The reduced toxicity was probably due to a weak distribution of the SEA D227A fusion protein in tissues with a high MHC class II expression and low systemic cytokine levels as exhibited in mice and rabbits. The data presented demonstrate the efficacy of immunoconjugates containing a mutated SAg in directing a T cell attack against tumor cells with minimal systemic immune activation.